WILEX receives acquisition offer from lifesciences advisor
This article was originally published in Clinica
WILEX has received a takeover bid of €4.10 per share from fellow German firm dievini Hopp BioTech. Under German law, lifesciences management advisor dievini is obliged to make an offer after it gained a 35.65% equity interest in WILEX on 2 June. The acceptance period for the offer runs from today until 12 August. WILEX (Munich) is a biopharmaceutical firm that develop drugs as well as diagnostic agents, such as radiolabelled antibodies, for the specific detection of tumours. Walldorf-based dievini consists of a team of experts in medicine, science, finance, legal and entrepreneurship, and is in charge of accompanying investors, management and enterprises.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals